API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 134 articles Forum Github 13 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. AU /
  3. RAC.AU

Race Oncology Ltd (RAC AU) stock market data APIs

A$1.66 -0.07(-4%) as of September 20, 2024
Price chart is built with Anychart

Race Oncology Limited, a clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments. The company's lead product is bisantrene, a small molecule chemotherapeutic that has a clinical history with demonstrated therapeutic benefits in adult and paediatric patients. It is advancing reformulated bisantrene (RC220) to address the unmet need of patients across various oncology indications with a clinical focus on anthracycline combination to deliver cardioprotection and enhanced anticancer activity in solid tumors. The company is also exploring RC220 as a low intensity treatment for acute myeloid leukaemia. In addition, it is investigating the effect of bisantrene on the m6A RNA pathway, following independent research identifying bisantrene as the potent inhibitor of fat mass and obesity-associated protein. The company has collaborations with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. The company was formerly known as Coronado Resources Limited. Race Oncology Limited was incorporated in 2011 and is headquartered in Sydney, Australia.

Race Oncology Ltd Financial Data Overview

1.73
1.66
-
1.73
1.64
0.64-2.09
280 M
170 M
4 003 K
1.743
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'RAC',
Type: 'Common Stock',
Name: 'Race Oncology Ltd',
Exchange: 'AU',
CurrencyCode: 'AUD',
CurrencyName: 'Australian Dollar',
CurrencySymbol: 'A$',
CountryName: 'Australia',
CountryISO: 'AU',
OpenFigi: 'BBG00CWVFMV0',
ISIN: 'AU000000RAC3',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'June',
IPODate: NULL,
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Biotechnology',
}

Race Oncology Ltd Fundamental Data is available in our Financial Data APIs

  • Net Revenue 4 003 K
  • EBITDA -14 203 376
  • Earnings Per Share -0.08
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Race Oncology Ltd Earnings via APIs

  • Latest Release 2024-08-27
  • EPS/Forecast NaN

Get Race Oncology Ltd End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Race Oncology Ltd latest news via APIs

Race Oncology announces deal with manufacturer Ardena to develop company’s new IV formulation RC220

Vancouver --News Direct-- Race Oncology Ltd Race Oncology CEO Damian Clark-Bruce joined Steve Darling from Proactive to share significant news about the company's recent agreements and partnerships. ...

Race executes agreement with Ardena for GMP manufacturing of RC220

Race Oncology executes agreement with leading global contract development and manufacturing organisation, Ardena as additional partner for GMP manufacturing of flagship RC220 bistanrene formulation Ar...
Do you have any questions?
support@eodhistoricaldata.com